cas 876343-10-1|| where to buy 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

製品名:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

IUPAC Name:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

包装単位	有効在庫	価格（USD）
CM104043-5g	in stock	șƅň
CM104043-10g	in stock	ƻşŭ
CM104043-25g	in stock	ƅşň

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 876343-10-1 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:876343-10-1; 分子式:C6H3ClIN3; 融点:-; SMILESコード:ClC1=C2C=C(I)NC2=NC=N1; 密度:

: カタログ番号:CM104043; 分子量:279.47; 沸点:; MDL番号:MFCD11518919; 保管方法:-20°C

: Pyrrolopyrimidines; Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

: BMF-219; Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.